Please find enclosed herewith transcript of earnings call held on November 03, 2026 for unaudited financial results for the quarter and half year ended September 30, 2026.

November 05, 2026 BSE Limited National Stock Exchange of India Ltd. Department of Corporate Affairs Exchange Plaza, Plot No. C/1, G Block P. J. Towers, Dalal Street, Bandra-Kurla Complex, Bandra (E) Mumbai- 400 001 Mumbai- 400 051 Scrip ID-540025 Scrip Code-ADVENZYMES Dear Sir/Madam, Sub: Transcript of Conference call held on November 03, 2026 for the Unaudited Financial Results for the quarter and half year ended September 30, 2026. In furtherance to our intimation letter dated October 26, 2026, please find enclosed herewith the Transcript of the Conference call held on Tuesday, November 03, 2026 with Analysts and Investors for the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. The aforesaid information is also being uploaded on the website of the Company. Kindly take same on your records. Thanking you, Yours Faithfully, For Advanced Enzyme Technologies Limited Sanjay Basantani Company Secretary and Head - Legal Encl.: As above “Advanced Enzyme Technologies Limited Q2 FY27 Earnings Conference Call” November 03, 2026 MANAGEMENT: MR. MUKUND KABRA – WHOLE TIME DIRECTOR – ADVANCED ENZYME TECHNOLOGIES LIMITED MR. BENI RAUKA – GROUP CHIEF FINANCIAL OFFICER – ADVANCED ENZYME TECHNOLOGIES LIMITED MR. RONAK SARAF – SENIOR MANAGER INVESTOR RELATIONS – ADVANCED ENZYME TECHNOLOGIES LIMITED Disclaimer: This is a transcription and may contain transcription errors. The transcript has been edited for clarity, readability, etc. The Company takes no responsibility of such errors, although an effort has been made to ensure high level of accuracy. Kindly Note, there could be unpublished price sensitive information that would have been shared /discussed during the call. Complying with the SEBI regulations, we have shared Audio Transcript to the Stock Exchanges and the Company website on November 03, 2026 for information of public at large. Page 1 of 14 Advanced Enzyme Technologies Limited November 03, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Advanced Enzyme Technologies Limited Q2 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Ronak Saraf. Thank you, and over to you, sir. Ronak Saraf: Thank you. Good evening, everyone. Welcome to Advanced Enzyme Technologies Q2 and H1 FY27 Earnings Conference Call. We sincerely hope you all have gone through our financial press release and the presentation, which has been posted in the Investor Relations section of our website as well as on the stock exchanges. We have with us Mr. Mukund Kabra, Whole-Time Director; and Mr. Beni Rauka, Group CFO. Today, the management will discuss the performance and business highlights, update on strategies and respond to any questions that you may have. As is usual, for ease of discussion, we will look at the consolidated financials. I would like to draw your attention to the fact that some of the information shared during this call, particularly regarding our plans, strategies and future outlook, may contain forward-looking statements. These statements involve inherent risks and uncertainties and are based on current expectations, forecasts and assumptions. Actual results may differ materially from those expressed or implied in these statements, influenced by a range of factors, including, but not limited to, economic conditions, changes in government policies, regulatory developments, and other unforeseen circumstances. Participants are cautioned not to place undue reliance on these forward-looking statements as they are not guarantees of future performance and should not be viewed as a substitute for independent judgment. The company undertakes no obligation to update or revise any such statements, whether as a result of new information, future events or otherwise. Now without any further ado, we shall commence this call. Over to you, Mukund, sir. Mukund Kabra: Thank you, Ronak. Good evening, everyone. Thank you for joining us today for our quarter 2 and half yearly earnings call. I extend a warm welcome to all our shareholders and partners. As the festive season is just around the corner, the entire AETL family would like to extend our warmest wishes to you and your loved ones. May this festival of lights fill your lives with happiness, prosperity, good health, and success. Wishing you and your family a joyful, bright, and wonderful Diwali. Before we discuss the performance for the quarter, we are pleased to announce that the company has successfully completed the buyback by acquiring 2.41 million equity shares at an average Page 2 of 14 Advanced Enzyme Technologies Limited November 03, 2026 price of INR289.09 per share via open market route. This reflects our continued commitment to enhancing shareholder value and maintaining a balanced approach towards capital allocation. On the global front, the economic environment continues to remain challenging, with geopolitical tensions across various regions creating uncertainty in international trade, supply chains and commodity markets. These developments, coupled with inflationary pressures, volatile energy prices and fluctuations in currency markets, continue to influence the overall business environment. While central banks across major economies remain focused on managing inflation and supporting growth, the pace of recovery remains uneven. In this environment, we continue to remain watchful, focused on operational efficiencies, prudent cost management and disciplined execution to navigate uncertainties while pursuing our long-term growth objectives. I'm happy to announce that we have reported robust numbers for the quarter 2 fiscal '27. We have witnessed growth across all business segments of our presence. Our quarter 2 number delivery reflects a strong growth. The fundamental strength of our business remain firmly intact, and we anticipate progressive momentum as the year advances. While it is important to view this performance in the context of the inherent nature of our business, that is the reason we always suggest all our shareholders to evaluate our business on an annual horizon rather than through the lens of a single quarter. Our top line for the quarter stood at INR2,145 million, registering a growth of 16% year-on-year and 12% on a sequential basis, while the first half of financial year '27 revenue grew by 10% over the corresponding period last year. EBITDA increased to INR721 crores, up 20% year-on-year and 36% sequentially, while the same grew by 7% on a year-to-date basis. Consequently, the EBITDA margin stood at 34% compared to 33% in quarter 2 financial year '26 and 28% in quarter 1 financial year '27. On YTD basis, this number remained unchanged at 31%. Although the input costs like power and fuel and raw material remained elevated during the quarter, but our focus on operational efficiencies eliminated the risk and delivered robust margins. We anticipate this sustainable growth and stronger performance throughout the rest of the year. Moving to profitability. Profit after tax, PAT, stood at INR512 million, grew by 14% year-on- year basis, 33% sequential basis and 5% on a YTD basis. The PAT margin for the quarter was 24% and 22% for the first half financial year '27. Now I will take you through our segment-wise revenue performance for the second quarter of financial year '27, and compare it both year-on-year, sequentially and year-to-date. Let's begin with Human Healthcare. Revenues for quarter 2 financial year '27 stood at INR1,285 million, reflecting a 6% Y-o-Y growth and 11% sequential increase. Page 3 of 14 Advanced Enzyme Technologies Limited November 03, 2026 This growth was primaril [Showing first 8,000 characters — download PDF for full document]